Research programme: PEGylated clotting factors - Shire/Nektar Therapeutics

Drug Profile

Research programme: PEGylated clotting factors - Shire/Nektar Therapeutics

Latest Information Update: 15 Jun 2016

Price : $50

At a glance

  • Originator Baxter International; Nektar Therapeutics
  • Developer Nektar Therapeutics; Shire
  • Class Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Blood coagulation factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haematological disorders; Haemophilia A

Most Recent Events

  • 03 Jun 2016 Baxalta has been acquired and merged into Shire
  • 09 Jan 2012 Preclinical trials in Haematological disorders in USA (Parenteral)
  • 20 Dec 2007 Nektar Therapeutics and Baxter International expand their agreement
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top